Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CDX 0158 · KTN-0158

Monoclonal antibody · Inhibitor of c-Kit (KIT) · developed by Celldex Therapeutics

Phase 1 Most advanced trial (none active)

CLDX Developer

1 Registered trials

What is CDX 0158?

CDX 0158 is a humanized IgG1 monoclonal antibody that binds the receptor tyrosine kinase c-Kit (CD117) and inhibits its activation, which blocks c-KIT-mediated signaling and proliferation in c-Kit-expressing cancer cells. It is being studied in advanced cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: KTN-0158
Drug type: Monoclonal antibody
Targets: c-Kit (KIT)
Mechanism: Inhibitor of c-Kit (KIT)
Pathways: c-KIT-mediated signal transduction, cell proliferation, mast cell activation and degranulation
Therapy area: Oncology
Developer: Celldex Therapeutics (CLDX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: DF2O3JG5D2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02642016	Phase 1	Advanced Cancer	Completed	CLDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Cancer

Other drugs acting on KIT

Midostaurin FDA approved Pexidartinib FDA approved Regorafenib FDA approved Sunitinib FDA approved Barzolvolimab Phase 3 Bezuclastinib Phase 3 Briquilimab Phase 1/2 Olverembatinib Phase 3 Sitravatinib Phase 3

More from Celldex Therapeutics

Barzolvolimab Phase 3 CDX-014 Phase 1 CDX-1140 Phase 2 CDX-1307 Phase 2 CDX-301 Phase 2 CDX-3379 Phase 2 CDX-527 Phase 1 CDX-585 Phase 1 CDX-622 Phase 1 Glembatumumab Vedotin Phase 2 Keyhole Limpet Hemocyanin Phase 2 Rindopepimut Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CLDX page.

Follow CLDX, the company behind CDX 0158

See CLDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLDX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z